Antifungal therapy in surgical ICU patients

Intensive Care Medicine: Annual Update 2006

Volumn , Issue , 2007, Pages 613-623

  Weigand, M A ^a   Lichtenstern, C ^a   Bottiger B W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892247523     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-35096-9_57     Document Type: Chapter

References (48)

1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
2. Blumberg HM, Jarvis WR, Soucie JM, et al (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177-186
3. Vincent JL, Anaissie E, Bruining H, et al (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 24:206-216
4. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA (1998) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 36:1886-1889
5. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP (1998) National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 30:121-129
6. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D (2002) Secular trends of candi-demia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 81:425-433
7. Rex JH, Sobel JD (2001) Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 32:1191-1200
8. Goodman JL, Winston DJ, Greenfield RA, et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845-851
9. Winston DJ, Pakrasi A, Busuttil RW (1999) Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:729-737
10. Petri MG, Konig J, Moecke HP, et al (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 23:317-325
11. Trick WE, Fridkin SK, Edwards JR, Haiieh RA, Gaynes RP (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35:627-630
12. Munoz P, Burillo A, Bouza E (2000) Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 15:83-90
13. Kam AP, Xu J (2002) Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis 43:19-28
14. Solomkin JS, Mazuski JE, Baron EJ, et al (2003) Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37:997-1005
15. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751-758
16. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28:1708-1717
17. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685-702
18. Stevens DA, Kan VL, Judson MA, et al (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30:696-709
19. Bates DW, Su L, Yu DT, et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693
20. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:120-127
21. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new "gold standard". Clin Infect Dis 37:415-425
22. Bates DW, Yu DT (2003) Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Bare) 39:801-813
23. Pappas PG, Rex JH, Sobel JD, et al (2004) Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
24. FDA, Antiviral Drugs Advisory Committee. (2001) Briefing Document for Voriconazole (Oral and Intravenous Formulations) Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefmg/3792b2Jl-pfizer.pdf#search= Antiviral%20Drugs%20Advisory%20Committee%20 and%20voriconazole. Accessed Oct 2005
25. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW (2004) Adverse reactions to voriconazole. Clin Infect Dis 39:1241-1244
26. Raad I, Chapman S, Bradsher R (2004) Posaconazole (POS) salvage therapy for invasive fungal infections (in). 44th ICAAC, Washington, abstract M-669
27. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142-1151
28. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH (2005) Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 33:1928-1935
29. Pelz RK, Hendrix CW, Swoboda SM, et al (2001) Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 233:542-548
30. Eggimann P, Francioli P, Bille J, et al (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066-1072
31. Walsh TJ, Teppler H, Donowitz GR, et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
32. Walsh TJ, Pappas P, Winston DJ, et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234
33. Klastersky J (2004) Antifungal therapy in patients with fever and neutropenia-more rational and less empirical? N Engl J Med 351:1445-1447
34. Dellinger RP, Carlet JM, Masur H, et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873
35. Mora-Duarte J, Betts R, Rotstein C, et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
36. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:651-655
37. Perfect JR, Marr KA, Walsh TJ, et al (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122-1131
38. Kullberg BJ, Pappas P, Ruhnke M, et al (2004) Voriconazole compared to a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. 14th ECCMID, Prague, Abstract Nr. 0245
39. Rex JH, Pappas PG, Karchmer AW, et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 36:1221-1228
40. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46:451-457
41. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529-1535
42. Villanueva A, Gotuzzo E, Arathoon EG, et al (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113:294-299
43. Ally R, Schurmann D, Kreisel W, et al (2001) A randomized, double-blind, double-dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447-1454
44. Sandven P, Qvist H, Skovlund E, Giercksky KE (2002) Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 30:541-547
45. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781-803
46. Denning DW, Ribaud P, Milpied N, et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571.
47. Maertens J, Raad I, Petrikkos G, et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
48. Herbrecht R, Denning DW, Patterson TF, et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415